<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39372823</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2376-0605</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>AACE clinical case reports</Title><ISOAbbreviation>AACE Clin Case Rep</ISOAbbreviation></Journal><ArticleTitle>Type 1 Diabetes Mellitus Caused by COVID-19 mRNA Vaccination: A Case Report and Literature Review of 17 Published Cases.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>183</EndPage><MedlinePgn>179-183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.aace.2024.06.001</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVE" NlmCategory="UNASSIGNED">Multiple cases of postvaccination immune-related adverse events have been reported. We, hereby, present a patient who presented with new-onset type 1 diabetes mellitus (DM) after COVID-19 messenger RNA (mRNA) vaccination.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="UNASSIGNED">A 38-year-old Caucasian man presented with sudden onset of polyuria, polydipsia, and blurry vision for 1 month. The patient received the second dose of the COVID-19 mRNA vaccine (Pfizer-BioNTech) 4 weeks prior to symptom onset. Initial workup revealed glucosuria and hemoglobin A1c of 9.4%. Antibodies against multiple pancreatic beta cell autoantigens were detected. The patient was then initiated on insulin.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Hypothesized mechanisms for development of type 1 DM after COVID-19 mRNA vaccination include molecular mimicry, autoimmune/inflammatory syndrome induced by adjuvants, and possible interaction between the angiotensin-I converting enzyme-2 receptor on beta cells and viral mRNA. An initial high index of suspicion should be accompanied by early autoantibody testing and initiation of insulin, if indicated. Finally, if diagnosed with type 1 diabetes, patients must have long-term follow-up as there may be brief periods where glycemic control is maintained off insulin.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">New-onset type 1 DM has been reported after COVID mRNA vaccination. Clinicians should maintain a high index of suspicion and pursue early testing for the same to reduce adverse outcomes and improve long-term prognosis.</AbstractText><CopyrightInformation>© 2024 AACE. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Unnati</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Nishant</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barjuca</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oakland University, Rochester, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halalau</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oakland University William Beaumont School of Medicine, Oakland University, Rochester, Michigan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AACE Clin Case Rep</MedlineTA><NlmUniqueID>101670593</NlmUniqueID><ISSNLinking>2376-0605</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HbA1c</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">insulin dependent</Keyword><Keyword MajorTopicYN="N">molecular mimicry</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372823</ArticleId><ArticleId IdType="pmc">PMC11447533</ArticleId><ArticleId IdType="doi">10.1016/j.aace.2024.06.001</ArticleId><ArticleId IdType="pii">S2376-0605(24)00056-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao Y., Wu X. Influence of COVID-19 vaccines on endocrine system. Endocrine. 2022;78:241–246. doi: 10.1007/s12020-022-03119-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03119-3</ArticleId><ArticleId IdType="pmc">PMC9244486</ArticleId><ArticleId IdType="pubmed">35751776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xu Z., Wang P., et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386–401. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z., Velásquez García H.A., Wong S., et al. Association of COVID-19 infection with incident diabetes. JAMA Netw Open. 2023;6 doi: 10.1001/jamanetworkopen.2023.8866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8866</ArticleId><ArticleId IdType="pmc">PMC10114057</ArticleId><ArticleId IdType="pubmed">37071420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon H., Suh S., Park M.K. Adult-onset type 1 diabetes development following COVID-19 mRNA vaccination. J Korean Med Sci. 2023;38 doi: 10.3346/jkms.2023.38.e12.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e12</ArticleId><ArticleId IdType="pmc">PMC9829515</ArticleId><ArticleId IdType="pubmed">36625174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin R., Lin Y.-W., Chen M.-H. Fulminant type 1 diabetes mellitus after SARS-CoV-2 vaccination: a case report. Vaccines (Basel) 2022;10:1905. doi: 10.3390/vaccines10111905.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111905</ArticleId><ArticleId IdType="pmc">PMC9692754</ArticleId><ArticleId IdType="pubmed">36423001</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydoğan B.İ., Ünlütürk U., Cesur M. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination. Endocrine. 2022;78:42–46. doi: 10.1007/s12020-022-03130-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03130-8</ArticleId><ArticleId IdType="pmc">PMC9282628</ArticleId><ArticleId IdType="pubmed">35809159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai K., Narita D., Saito N., et al. Type 1 diabetes mellitus following COVID-19 RNA-based vaccine. J Diabetes Investig. 2022;13:1290–1292. doi: 10.1111/jdi.13781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13781</ArticleId><ArticleId IdType="pmc">PMC9114989</ArticleId><ArticleId IdType="pubmed">35220662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano M., Morioka T., Natsuki Y., et al. New-onset type 1 diabetes after COVID-19 mRNA vaccination. Intern Med. 2022;61:1197–1200. doi: 10.2169/internalmedicine.9004-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.9004-21</ArticleId><ArticleId IdType="pmc">PMC9107966</ArticleId><ArticleId IdType="pubmed">35135929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Yakou F., Saburi M., et al. New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: a case report. Clin Case Rep. 2022;10 doi: 10.1002/ccr3.6473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.6473</ArticleId><ArticleId IdType="pmc">PMC9576963</ArticleId><ArticleId IdType="pubmed">36267825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kshetree B., Lee J., Acharya S. COVID-19 vaccine-induced rapid progression of prediabetes to ketosis-prone diabetes mellitus in an elderly male. Cureus. 2022;14 doi: 10.7759/cureus.28830.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.28830</ArticleId><ArticleId IdType="pmc">PMC9535996</ArticleId><ArticleId IdType="pubmed">36225440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleve E., Venditti V., Lenzi A., et al. COVID-19 vaccine and autoimmune diabetes in adults: report of two cases. J Endocrinol Invest. 2022;45:1269–1270. doi: 10.1007/s40618-022-01796-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-022-01796-5</ArticleId><ArticleId IdType="pmc">PMC8960710</ArticleId><ArticleId IdType="pubmed">35349113</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki H., Itoh A., Watanabe Y., et al. Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: a case report. J Diabetes Investig. 2022;13:1105–1108. doi: 10.1111/jdi.13757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13757</ArticleId><ArticleId IdType="pmc">PMC9153841</ArticleId><ArticleId IdType="pubmed">35088548</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrizio A., Ferrari S.M., Antonelli A., et al. A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125 doi: 10.1016/j.jaut.2021.102738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102738</ArticleId><ArticleId IdType="pmc">PMC8506108</ArticleId><ArticleId IdType="pubmed">34653776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Kodama S., Kaneko K., et al. Type 1 diabetes mellitus associated with nivolumab after second SARS-CoV-2 vaccination, Japan. Emerg Infect Dis. 2022;28:1518–1520. doi: 10.3201/eid2807.220127.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2807.220127</ArticleId><ArticleId IdType="pmc">PMC9239866</ArticleId><ArticleId IdType="pubmed">35468049</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki K., Morioka T., Okada N., et al. New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. J Diabetes Investig. 2022;13:1286–1289. doi: 10.1111/jdi.13771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13771</ArticleId><ArticleId IdType="pmc">PMC9114923</ArticleId><ArticleId IdType="pubmed">35167186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohuchi K., Amagai R., Tamabuchi E., et al. Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. J Dermatol. 2022;49:e167–e168. doi: 10.1111/1346-8138.16304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.16304</ArticleId><ArticleId IdType="pubmed">35014070</ArticleId></ArticleIdList></Reference><Reference><Citation>Makiguchi T., Fukushima T., Tanaka H., et al. Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: a case report. Thorac Cancer. 2022;13:1220–1223. doi: 10.1111/1759-7714.14352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.14352</ArticleId><ArticleId IdType="pmc">PMC9013655</ArticleId><ArticleId IdType="pubmed">35166047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020;11 doi: 10.3389/fimmu.2020.617089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Watad A., Bragazzi N.L., McGonagle D., et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: insights from an analysis of 500 cases. Clin Immunol. 2019;203:1–8. doi: 10.1016/j.clim.2019.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.03.007</ArticleId><ArticleId IdType="pubmed">30922961</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-T., Lidsky P.V., Xiao Y., et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021;33:1565–1576.e5. doi: 10.1016/j.cmet.2021.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC8130512</ArticleId><ArticleId IdType="pubmed">34081912</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>